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rate of synchronous metastatic disease. Small renal tumors 
<4 cm in size have a low risk of synchronous metastatic dis-
ease. The risk becomes significantly associated with tumor 
size for tumors  ≤ 5 cm.  © 2014 S. Karger AG, Basel 
 Introduction 
 Renal cell cancer (RCC) accounts for over 4% of all 
malignancies diagnosed in males and over 3% in females. 
According to recent evaluations, at the time of first diag-
nosis of RCC, metastatic disease is seen in 25–35% of all 
cases  [1] , making curative treatment impossible in most 
of them. Metastatic disease is related to the size of the pri-
mary RCC  [2–4] . However, recently this has been chal-
lenged for the subgroup of primary RCC <4 cm in diam-
eter  [5] . If this were to be confirmed, it would have impli-
cations for the treatment of small renal masses.
 With increased use of modern imaging techniques  [6] , 
the incidence of small renal masses diagnosed inciden-
tally has risen  [7] . It is being discussed whether surgical 
treatment of small incidental renal masses is always war-
ranted or whether it represents overtreatment generally 
or under certain circumstances, such as high comorbidity 
and/or short life expectancy. Therefore, less invasive 
 Key Words 
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 Abstract 
 Objectives: To investigate the controversially discussed re-
lationship between tumor size and the occurrence of prima-
ry synchronous metastatic disease in renal cell cancer (RCC). 
 Patients and Methods: A consecutive RCC cohort of 2,058 
patients (150 primary metastatic) who underwent surgery 
between 1995 and 2010 was investigated. Rates of synchro-
nous metastases were calculated for stratified groups of tu-
mor size. Uni- and multivariate logistic regression models 
were calculated for the correlation of tumor size with pri-
mary metastatic disease.  Results: The rate of metastatic dis-
ease increased with increasing tumor size. Tumor size was 
significantly correlated with synchronous metastatic disease 
(p < 0.001, c-index 0.772), but for RCCs  ≤ 4 cm in size no sig-
nificant correlation was found. Regarding tumors  ≤ 5 cm in 
size, the correlation became significant (p = 0.028, c-index 
0.621). A multivariate logistic regression model for the pre-
diction of synchronous metastatic disease including tumor 
size, age and comorbidity yielded a significant c-index of 
0.82 and was used to construct a nomogram.  Conclusion: 
Our data confirm the correlation between tumor size and the 
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managements such as cryotherapy, radiofrequency abla-
tion or active surveillance are proposed and are presently 
being evaluated  [8] . However, one caveat of these man-
agement approaches to small renal masses is the possibil-
ity of undertreatment in cases where synchronous meta-
static disease has remained undiagnosed. If there is a con-
siderable risk of metastatic disease in incidental small 
renal masses, at least full staging would be required before 
deciding on management. The aim of this study was to 
evaluate in our own large series of RCC cases treated sur-
gically whether primary tumor size is a reliable predictor 
for the risk of synchronous metastatic disease in small 
RCCs and to evaluate other risk factors for metastatic dis-
ease in small RCCs in a multivariate model.
 Patients and Methods 
 This is a retrospective analysis of a prospectively maintained 
patient database. The cohort of all consecutive renal tumor cases 
treated surgically at the Department of Urology of the Technical 
University Dresden was extracted from our RCC database. Pa-
tients had undergone surgery between 1995 and 2010. The data-
base contained 2,214 patients. Cases with multiple or synchronous 
bilateral tumors, Bellini duct carcinoma or oncocytoma were ex-
cluded, leaving 2,058 cases for our analysis ( fig.  1 ). The tumor 
characteristics and patient demographics are listed in  table  1 . 
 Table 2 lists the distribution of metastatic patterns in patients with 
more than one metastatic site.
 The standard treatment in our department is open partial ne-
phrectomy, which was performed whenever feasible. Larger tu-
mors or those with central extension and/or vascular infiltration 
underwent open or laparoscopic radical nephrectomy. Staging 
included abdominal ultrasound, CT scan and chest X-ray in all 
cases. Tumors were stratified according to size and the frequen-
cy of synchronous metastatic disease in the different groups was 
calculated.
 Patient data were used for modeling a logistic regression mod-
el exploring the relationship between primary tumor size and syn-
chronous metastatic disease applying the lrm function of the rms 
library as described by Harrell et al.  [9] . The model test statistics 
were calculated in an equivalent to a contingency table χ 2 ap-
proach. The performance of the model was calculated using the 
c-index  [9] . A c-index of 1.0 indicates a perfect discrimination be-
tween patients with different outcome, which was defined as syn-
chronous metastatic disease or no synchronous metastatic disease. 
A c-index value of 0.5 signifies no discriminatory predictive value 
at all. Primary tumor size was used as a continuous variable in this 
model.
 Regression modeling initially was done for the whole cohort. 
For testing the correlation between tumor size and metastatic dis-
ease in small tumors exclusively, the same model was constructed 
for tumors  ≤ 4,  ≤ 5 and  ≤ 6 cm. These different sizes were chosen 
because the literature describes no correlation for tumors  ≤ 4 cm, 
but it has not been shown at which size threshold predictive mod-
els become valid.
Database cohort
n = 2,214
n = 156 excluded
(synchronous bilateral,
multiple tumors, Bellini
duct carcinoma, oncocytomas)
n = 2,058 in analysis
n = 150 metastatic n = 1,908 non-metastatic
 Fig. 1. Consort diagram of the study population and flow within 
the study. 
Table 1.  Tumor characteristics and patient demographics of the 
whole cohort of RCC cases (WHO TNM classification 2002)
Median age in years (IQR) 64 (14)
Gender, male/female 1,338/720 (65/35)
pT (2002 TNM)
pT1a 774 (38%)
pT1b 620 (30%)
pT2 232 (11%)
pT3a 185 (9%)
pT3b/c 230 (11%)
pT4 17 (<1%)
cN
cN0 1,959 (95%)
cN1/2 99 (5%)
cM
cM0 1,908 (93%)
cM1 150 (7%)
Grading
G1 250 (12%)
G2 1,486 (72%)
G3 307 (15%)
G4 6 (<1%)
Unknown 9 (<1%)
Median pathological size, cm (IQR) 4.5 (4.0)
Histology
Clear cell 1,588 (77%)
Papillary 224 (11%)
Chromophobe 194 (9%)
Unclassified 52 (3%)
Most frequent metastatic sites
Lung 103
Adrenal 38
Bone 36
Liver 20
Brain 10
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 For better accuracy in predicting the risk of synchronous meta-
static disease, a multivariate model was constructed using the co-
variates age and American Society of Anesthesiologists (ASA) score, 
again applying the lrm function of the rms library  [9] . For testing 
the significance of the three covariates, Wald testing was applied. 
The model was internally validated by the validate function of the 
rms library and the performance of the model was then calculated 
using the c-index  [9] . Finally, the model was presented graphically 
as a nomogram using the nomogram function of the rms library.
 All statistical analyses were performed using R TM , version 2.8.1 
(R Foundation for Statistical Computing). The reported p values 
are two-sided with the statistical significance level set at p  ≤ 0.05.
 Results 
 Within the whole cohort, the rate of synchronous 
 metastatic disease increased with increasing tumor size 
( table 3 ). For small renal tumors  ≤ 4 cm in size there was 
a low risk of synchronous metastatic disease, as only 
17/791 (2.1%) patients presented with metastases at first 
diagnosis in this group. Within the group of small RCCs 
( ≤ 4 cm) there was an obvious increase in the rate of pri-
mary metastatic disease between RCCs  ≤ 3 cm (1.6%) and 
those with tumors between 3.1 and 4 cm (2.8%), although 
this observation cannot be validated statistically due to 
the low number of primary metastases in this group.
 The univariate logistic regression model examining the 
relationship between tumor size and synchronous meta-
static disease for the whole study cohort yielded a definite 
and significant increase in metastatic risk with increasing 
size of the primary tumor (p < 0.001, c-index 0.772;  fig. 2 ). 
Since data from the literature do question this significant 
increase for tumors <4 cm in size, the same calculations 
Table 3.  Rates of synchronous metastatic disease in separate 
groups of primary tumor size
Tumor size, cm n M0 M1 % M1
0.2–3.0 428 421 7 1.6
3.1–4.0 363 353 10 2.8
4.1–5.0 299 289 10 3.3
5.1–6.0 236 227 9 3.8
6.1–7.0 199 185 14 7.0
7.1–8.0 147 130 17 11.6
8.1–9.0 107 94 13 12.1
9.1–10.0 93 71 22 23.7
10.1–11.0 65 53 12 18.5
11.1–12.0 28 19 9 32.1
12.1–13.0 27 19 8 29.6
13.1–14.0 22 14 8 36.4
14.1–15.0 17 16 1 5.9
≥15.1 27 17 10 37.0
Table 2.  Distribution patterns of primary metastatic disease in 
multiple organs
Number
Two organs
Lung, bones 11
Lung, liver 7
Lung, brain 6
Lung, adrenal gland 5
Lung, mediastinum 5
Bone, adrenal gland 2
Lung, thyroid gland 1
Liver, spleen 1
Adrenal gland, abdominal wall 1
Lung, epididymis 1
Liver, pancreas 1
Brain, supraclavicular 1
Three organs
Lung, liver, bones 4
Lung, liver, adrenal gland 2
Lung, adrenal gland, mediastinum 1
Lung, bones, mediastinum 1
Liver, adrenal gland, mediastinum 1
Lung, adrenal gland, bones 1
Lung, liver, mediastinum 1
Four organs
Lung, liver, adrenal gland, mediastinum 1
Lung, bones, adrenal gland, brain 1
Size, cm
lo
g 
od
ds
–4
–3
–2
–1
0
5 10 15
 Fig. 2. Regression line of the univariate model showing an increase 
of the log odds for synchronous metastatic disease with increasing 
primary tumor size (p < 0.001). The calculated c-index of the mod-
el is 0.772. 
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were applied to the group of small RCCs only ( ≤ 4 cm) and 
a comparable logistic regression model was calculated. 
For these small tumors, however, the logistic regression 
model did not show a significant association between pri-
mary tumor size and metastatic risk (p = 0.165, c-index 
0.593). This raised the question whether there is a size 
threshold where the logistic regression model becomes 
significant. Therefore the regression model was calculated 
for tumors  ≤ 5 cm and  ≤ 6 cm in size. For both thresholds 
the model was significant ( ≤ 5 cm: p = 0.028, c-index 0.621; 
 ≤ 6 cm: p = 0.017, c-index 0.609).
 A multivariate predictive model designed to test the 
predictive power for synchronous metastatic disease in-
cluded primary tumor size, patient age and ASA score as 
a comorbidity measure. Inside the model, ASA score (p = 
0.0003) and tumor size (p < 0.0001) were highly signifi-
cant predictors. Age did not reach significance (p = 
0.3894). Internal validation of the model produced a c-
index of 0.82, i.e. the model was able to predict synchro-
nous metastatic disease with relatively high accuracy. Fi-
nally, a nomogram was designed ( fig. 3 ).
 Discussion 
 The plausible notion that primary tumor size corre-
lates with or predicts progression-free and cancer-spe-
cific survival is generally accepted and has been shown 
for many carcinoma entities, including RCC  [10–12] . 
Thus, primary tumor size is an important factor for the 
management of RCC and also for the management of 
follow-up.
 However, when discussing conservative management 
in incidentally detected small renal masses, the question 
of the true risk of synchronous metastatic disease be-
comes crucial and there is some controversy on this issue 
 [13, 14] . Data from a multicenter study reported a rela-
tively high rate of synchronous metastatic disease in 
RCCs <4 cm in size  [5] . In that series, there was no sig-
nificant relationship between the rate of synchronous 
metastatic disease and primary tumor size in tumors 
<4  cm. However, when not only small tumors but all 
RCCs were considered, increasing tumor size correlated 
significantly with the rate of synchronous metastatic dis-
ease in other studies  [2, 15] . In our RCC database, which 
has been prospectively maintained since 1995, we could 
confirm the significant relationship between primary tu-
mor size and the rate of primary metastatic disease.
 791 out of the 2,058 patients in our series had primary 
RCCs with a diameter  ≤ 4 cm, and of those only 2.1% had 
synchronous metastatic disease. Others reported 9/1,227 
(0.7%) patients with primary metastatic disease in RCCs 
 ≤ 4 cm  [4] . Klatte et al.  [5] in their multicenter analysis 
reported a rate of primary metastatic disease of 7, 6, 5 and 
8% for RCCs of 0.1–1, 1.1–2, 2.1–3 and 3.1–4 cm in diam-
eter, respectively.
Points
0 10 20 30 40 50 60 70 80 90 100
Size
0 0.5 1 1.5 2 2.5 3 3.5 4
ASA
1 3
2 4
Age
90 80 70 60 50 40 30 20
Total points
0 50 100 150 200 250 300 350 400 450
Probability of metastasis
0.01 0.02 0.05 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.95
 Fig. 3. Nomogram representing a multivariate model for the prediction of synchronous metastatic disease including the variables patient 
age, ASA score and primary tumor size (cm). 
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 How can such a discrepancy be explained? Looking at 
the series of Klatte et al.  [5] in terms of raw numbers, 
34/575 (5.9%) cases of synchronous metastatic disease 
were reported for RCCs between 0.1 and 3 cm and 8% 
(38/420) for RCCs between 3.1 and 4 cm in size. Thus, 
there was a markedly higher rate of synchronous meta-
static disease in the group of larger tumors (3–4 cm) 
among all small RCCs. Pahernik et al.  [15] reported 3.0%, 
2.6% and 6.0% synchronous metastatic disease in the 
RCC size groups of 0.1–2, 2.1–3 and 3.1–4 cm, respec-
tively. Their series included a significant number of cases 
with multifocal tumors, and these represent an increased 
overall tumor burden; this may lead to an underestima-
tion of the relationship between primary tumor size and 
synchronous metastatic disease. However, both the series 
by Pahernik et al.  [15] and that by Klatte et al.  [5] show a 
definite increase in the rate of synchronous metastatic 
disease in RCCs between 3 and 4 cm in size, as does our 
series. Likewise, a Surveillance, Epidemiology, and End 
Results database analysis by Lughezzani et al.  [3] also 
found a relatively high rate of synchronous metastatic 
disease in small RCCs with a definite increase in the larg-
er of the small RCCs (4.8% at  ≤ 1.0 cm, 4.2% at 1.1–2.0 cm, 
4.9% at 2.1–3.0 cm and 7.1% at 3.1–4 cm, respectively). 
Thus, our results are in line with those of others, confirm-
ing a certain risk of synchronous metastatic disease in 
small RCCs <4 cm in diameter which lies between 2.1% 
(present series) and 5%. However, the risk is much high-
er in the larger of the small RCCs (3–4 cm) and seems to 
increase out of proportion in this group – 2.8% (our se-
ries) to 8%  [5] .
 It clearly depends on the subgroup of RCC cases in-
cluded in a given series whether a strong quantitative re-
lationship between tumor size and the rate of synchro-
nous metastatic disease can be calculated. Within the sub-
group of small RCCs, statistical significance will be more 
difficult to reach as the rate of observed cases with meta-
static disease will be rather low. This may explain our 
findings for RCCs  ≤ 4 cm and is in agreement with those 
of others  [5] . Regarding the uncertainty in predicting syn-
chronous metastatic disease in small renal masses  ≤ 4 cm 
in size, it is of interest to determine when a prediction 
model would become significant, i.e. whether there is a 
certain size threshold. We tried to determine such a 
threshold by calculating models for tumors  ≤ 5 cm and 
 ≤ 6 cm in size. Interestingly, the model became significant 
when we extended the cohort to tumors  ≤ 5 cm. This cor-
relation for tumors up to 5 cm shows that even for small-
er renal masses tumor size has a predictive potential re-
garding synchronous metastatic disease.
 The second aim of our study was to develop a multi-
variate model which might better predict the presence of 
synchronous metastatic disease. This aim was achieved 
for the whole range of tumor sizes by using readily avail-
able parameters such as the ASA score and patient age. 
Both parameters, although seemingly not directly related 
to metastatic potential, have been shown to be useful as 
both patient age and performance, which is related to co-
morbidity, have been shown to be predictive factors for 
survival in RCC disease  [16–23] . As our database does not 
include a performance score for all patients, we used the 
ASA score as an index of comorbidity. The validity of the 
ASA score as a prognostic factor for survival has recently 
been shown in a univariate model  [20, 21] .
 Our model performed well for the whole cohort of 
RCC cases (c-index of 0.82) and thus might have a poten-
tial application in cases where the question arises wheth-
er additional staging procedures should be performed be-
fore deciding on management.
 In summary, small RCCs  ≤ 4 cm in diameter have a low 
but not insignificant risk of synchronous metastatic dis-
ease. However, this risk increases considerably in RCCs 
between 3 and 4 cm in size and becomes significant when 
tumors up to 5 cm are included in a predictive model. Ex-
pectant management of small RCCs bears a definite risk, 
above all in tumors between 3 and 4 cm in size. Likewise, 
before undertaking surgical treatment in these cases, ad-
ditional staging to exclude primary synchronous meta-
static disease might be warranted in case of further risk 
factors such as older age and increased comorbidity. 
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